Pantoloc潘妥洛克

Pantoloc

pantoprazole

Manufacturer:

Takeda

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Pantoprazole Na
Indications/Uses
20-mg tab: Treatment of mild GERD & associated symptoms. Long-term management & prevention of relapse in reflux oesophagitis. Prevention of gastroduodenal ulcers induced by nonselective NSAIDs in patients at risk w/ a need for continuous NSAID treatment. 40-mg tab: Reflux oesophagitis in adults & adolescents ≥12 yr. Eradication of H. pylori in combination w/ appropriate antibiotic therapy in adult patients w/ H. pylori-associated ulcers; gastric & duodenal ulcer, Zollinger-Ellison syndrome & other pathological hypersecretory conditions in adults. IV: Duodenal & gastric ulcer, moderate & severe reflux esophagitis. Zollinger-Ellison syndrome & other hypersecretory conditions.
Dosage/Direction for Use
20-mg tab Treatment of mild GERD & associated symptoms 1 tab (20 mg)/day. Long-term management & prevention of relapse in reflux oesophagitis 1 tab (20 mg)/day, increased to 40 mg/day if a relapse occurs. Prevention of gastroduodenal ulcers induced by nonselective NSAIDs in patients at risk w/ a need for continuous NSAID treatment 1 tab (20 mg)/day. Patients w/ severe hepatic impairment 20 mg daily. 40-mg tab Adult & adolescent ≥12 yr Reflux oesophagitis 1 tab (40 mg) daily for 4 wk, may be increased to 2 tab daily. Adult Eradication of H. pylori in combination w/ 2 appropriate antibiotics 1 tab (40 mg) bd w/ combination of amoxicillin 1,000 mg bd & clarithromycin 500 mg bd; or w/ combination of metronidazole 400-500 mg (or tinidazole 500 mg) bd & clarithromycin 250-500 mg bd; or w/ combination of amoxicillin 1,000 mg bd & metronidazole 400-500 mg (or tinidazole 500 mg) bd. Gastric ulcer 1 tab (40 mg) daily for 4 wk, may be increased to 2 tab daily. Duodenal ulcer 1 tab (40 mg) daily for 2 wk, may be increased to 2 tab daily. Zollinger-Ellison syndrome & other pathological hypersecretory conditions Initially 80 mg daily & should be adapted according to clinical needs. IV Duodenal & gastric ulcer, moderate & severe reflux esophagitis 40 mg/day. Zollinger-Ellison syndrome & other hypersecretory conditions Initially 80 mg daily for long-term management, titrated up or down as needed. Doses >80 mg, divide dose & give bd. For rapid acid control, starting dose of 2 x 80 mg w/in 1 hr.
Administration
Should be taken on an empty stomach: Take 1 hr before meals. Swallow whole, do not chew/crush.
Contraindications
Hypersensitivity to pantoprazole or to substituted benzimidazoles.
Special Precautions
May mask symptoms of gastric malignancy. May reduce vit B12 absorption due to hypo- or achlorhydria in patients w/ Zollinger-Ellison syndrome & other pathological hypersecretory conditions requiring long-term treatment. Patients on long-term treatment should be kept under regular surveillance. Risk of GI infections; osteoporosis-related fractures of the hip, wrist, or spine; symptomatic or asymptomatic hypomagnesemia; subacute cutaneous lupus erythematosus (SCLE). Increased Chromogranin A level may interfere w/ investigations for neuroendocrine tumors. Not recommended to be co-administered w/ HIV PIs. Regularly monitor liver enzymes, particularly on long-term use, in patients w/ severe liver impairment. Pregnancy & lactation. 40-mg tab: Must not be used in combination treatment for eradication of H. pylori in patients w/ moderate to severe hepatic dysfunction or patients w/ impaired renal function. Not recommended in childn <12 yr. IV: Patients on controlled Na diet. Childn <18 yr.
Adverse Reactions
Benign fundic gland polyphs; inj site thrombophlebitis (for IV); diarrhea, headache.
Drug Interactions
May interfere w/ absorption of pH-dependent medicinal products eg, some azole antifungals (eg, ketoconazole, itraconazole, posaconazole) & other medicine (eg, erlotinib). Reduction in bioavailability of HIV PIs eg, atazanavir. Increased INR & prothrombin time w/ coumarin anticoagulants eg, warfarin or phenprocoumon. May elevate & prolong serum levels of methotrexate &/or its metabolite. Potential increased systemic exposure w/ CYP2C19 inhibitors eg, fluvoxamine. Potential reduced plasma conc w/ CYP2C19 & CYP3A4 inducers eg, rifampicin & St. John's wort.
ATC Classification
A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Presentation/Packing
Form
Pantoloc inj 40 mg
Packing/Price
1's
Form
Pantoloc tab 20 mg
Packing/Price
14's
Form
Pantoloc tab 40 mg
Packing/Price
14's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in